Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
27 Outubro 2023 - 8:00AM
Monte Rosa Therapeutics, a clinical-stage biotechnology company
developing novel molecular glue degrader (MGD)-based medicines,
today announced that management will participate in the following
investor conferences:
- TD Cowen 7th Annual Fall Oncology
Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00
p.m. ET
- Jefferies London Healthcare
Conference (London, UK) – Investor meetings, November 14-15,
2023
The webcasted presentation will be accessible
via the “Events & Presentations” section of Monte Rosa’s
website at ir.monterosatx.com, and an archived version will be made
available for 90 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage
biotechnology company developing highly selective molecular glue
degrader (MGD) medicines for patients living with serious diseases
in the areas of oncology, autoimmune and inflammatory diseases, and
more. MGDs are small molecule protein degraders that have the
potential to treat many diseases that other modalities, including
other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and
Engineered Elimination of Neosubstrates) discovery engine combines
AI-guided chemistry, diverse chemical libraries, structural biology
and proteomics to identify degradable protein targets and
rationally design MGDs with unprecedented selectivity. The QuEEN
discovery engine enables access to a wide-ranging and
differentiated target space of well-validated biology across
multiple therapeutic areas. Monte Rosa has developed the industry’s
leading pipeline of MGDs, which spans oncology, autoimmune and
inflammatory disease and beyond. For more information, visit
www.monterosatx.com.
InvestorsAndrew Funderburk, Kendall
IRir@monterosatx.com
MediaCory Tromblee, Scient
PRmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024